Search research articles
Contact Us
Filters
Showing results (41-50 of 47) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 47 results.
The British Journal of Dermatology
|
September 24, 2020
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study
M J Cork, D Thaçi, L F Eichenfield, et al.
Clinical and Experimental Immunology
|
February 7, 2009
Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy
M Hong, K R Ryan, P D Arkwright, et al.
Journal of Clinical Immunology
|
February 10, 2015
Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe
A J Turley, B Gathmann, C Bangs, et al.
The British Journal of Dermatology
|
October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
M J Cork, D Thaçi, L F Eichenfield, et al.
Clinical and Experimental Immunology
|
June 8, 2018
The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017
B Shillitoe, C Bangs, D Guzman, et al.
Blood
|
January 3, 2001
V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations
A Villa, C Sobacchi, L D Notarangelo, et al.
Clinical and Experimental Immunology
|
July 12, 2013
The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 years' activity 2008-2012
J D M Edgar, M Buckland, D Guzman, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 47) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 47 results.
The British Journal of Dermatology
|
September 24, 2020
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study
M J Cork, D Thaçi, L F Eichenfield, et al.
Clinical and Experimental Immunology
|
February 7, 2009
Pattern recognition receptor expression is not impaired in patients with chronic mucocutanous candidiasis with or without autoimmune polyendocrinopathy candidiasis ectodermal dystrophy
M Hong, K R Ryan, P D Arkwright, et al.
Journal of Clinical Immunology
|
February 10, 2015
Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe
A J Turley, B Gathmann, C Bangs, et al.
The British Journal of Dermatology
|
October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
M J Cork, D Thaçi, L F Eichenfield, et al.
Clinical and Experimental Immunology
|
June 8, 2018
The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017
B Shillitoe, C Bangs, D Guzman, et al.
Blood
|
January 3, 2001
V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations
A Villa, C Sobacchi, L D Notarangelo, et al.
Clinical and Experimental Immunology
|
July 12, 2013
The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 years' activity 2008-2012
J D M Edgar, M Buckland, D Guzman, et al.
Page
of 5